Chemoinformaics analysis of ENT-16BETA,17-EPOXY-KAURANE
| Molecular Weight | 288.475 | nRot | 0 |
| Heavy Atom Molecular Weight | 256.219 | nRig | 22 |
| Exact Molecular Weight | 288.245 | nRing | 5 |
| Solubility: LogS | -6.193 | nHRing | 1 |
| Solubility: LogP | 5.794 | No. of Aliphatic Rings | 5 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 53 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 32 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 55.5394 |
| nHD | 0 | BPOL | 33.8386 |
| QED | 0.559 |
| Synth | 5.878 |
| Natural Product Likeliness | 3.372 |
| NR-PPAR-gamma | 0.025 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.015 |
| Pgp-sub | 0 |
| HIA | 0.004 |
| CACO-2 | -5.029 |
| MDCK | 0.0000188 |
| BBB | 0.397 |
| PPB | 0.97631 |
| VDSS | 1.537 |
| FU | 0.0213153 |
| CYP1A2-inh | 0.052 |
| CYP1A2-sub | 0.591 |
| CYP2c19-inh | 0.127 |
| CYP2c19-sub | 0.932 |
| CYP2c9-inh | 0.221 |
| CYP2c9-sub | 0.577 |
| CYP2d6-inh | 0.189 |
| CYP2d6-sub | 0.786 |
| CYP3a4-inh | 0.52 |
| CYP3a4-sub | 0.2 |
| CL | 15.987 |
| T12 | 0.052 |
| hERG | 0.013 |
| Ames | 0.018 |
| ROA | 0.062 |
| SkinSen | 0.151 |
| Carcinogencity | 0.037 |
| EI | 0.452 |
| Respiratory | 0.944 |
| NR-Aromatase | 0.737 |
| Antiviral | No |
| Prediction | 0.656426 |